Business Context and Reporting Period
This Form 8-K is a current report filed by Cerecor Inc. (not Avalo Therapeutics, Inc.) on June 18, 2020. The filing documents events occurring at the Company's 2020 Annual Meeting of Stockholders held on the same date. Cerecor Inc. is a Delaware corporation with its principal executive offices in Rockville, Maryland, and its common stock trades on the Nasdaq Capital Market under the symbol "CERC".
Key Financial Metrics
This filing is a current report regarding corporate governance and equity plan approvals. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial performance metrics.
Material Changes and Corporate Actions
- Equity Incentive Plan Approval: Stockholders approved the "Cerecor Inc. Third Amended and Restated 2016 Equity Incentive Plan." This action increases the total number of shares of common stock reserved for issuance under the Plan to 11,815,408 shares.
- Board of Directors Election: Seven nominees were elected to the Board of Directors to serve until the 2021 Annual Meeting. All nominees received significant majority support.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, specific risks, contingencies, or unusual items. The document focuses exclusively on the results of the stockholder vote and the amendment of the equity incentive plan.
Investor Verification Checklist
- Verify the full text of the Third Amended and Restated 2016 Equity Incentive Plan filed as Exhibit 10.1 to understand vesting schedules and eligibility.
- Review the 2020 Proxy Statement (filed April 28, 2020) for detailed background on the equity plan proposal and director nominees.
- Confirm the share count impact of the increased reserve (11,815,408 shares) on potential future dilution.
- Check subsequent filings for the Company's actual financial performance, as this 8-K contains no financial data.